Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

Journal of Experimental Medicine

Volumn 180, Issue 3, 1994, Pages 1141-1146

  Detmar, Michael ^a   Brown, Lawrence F ^a   Claffey, Kevin P ^a   Yeo, Kiang Teck ^a   Kocher, Olivier ^a   Jackman, Robert W ^a   Berse, Brygida ^a   Dvorak, Harold F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN SITU HYBRIDIZATION; MICROVASCULATURE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; VASCULAR ENDOTHELIUM;

BASE SEQUENCE; CELLS, CULTURED; ENDOTHELIAL GROWTH FACTORS; HUMAN; LYMPHOKINES; MOLECULAR SEQUENCE DATA; PSORIASIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0027980960     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.180.3.1141     Document Type: Article

References (46)

1. Weinstein G.D., J.L. McCullough, and P.A. Ross. 1985. Cell kinetic basis for pathophysiology of psoriasis.J. Invest. Dermatol. 85:579.
2. Fry L. 1988. Psoriasis. Sr. J. Dermatol 119:445.
3. Christophers E., R. Parzefall, and O. Braun-Falco. 1973. Initial events in psoriasis: quantitative assessment. Br. J. Dermatol. 89:327.
4. Ryan T.J. 1980. Microcirculation in psoriasis. Pharmacol. & Ther. (B). 10:27.
5. Braverman I.M., and A. Keh-Yen. 1986. Three-dimensional reconstruction of endothelial cell gaps in psoriatic vessels and their morphologic identity with gaps produced by the intradermal injection of histamine. J. Invest. Dermatol. 86:577.
6. Bull R.H., D.O. Bates, and P.S. Mortimer. 1992. Intravital video-capillaroscopy for the study of microcirculation in psoriasis. Br. J. Dermatol. 126:436.
7. Braverman I.M., and J. Sibley. 1982. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J. Invest. Dermatol. 78:12.
8. Jungkunz W., M. Eichhorn, J. Wörl, W.C. Marsch, and H. Holzmann. 1992. Carbonic anhydrase—a marker for fenestrated capillaries in psoriasis. Arch. Dermatol. Res. 284:146.
9. Pinkus H., and A.H. Mehregan. 1966. The primary histologic lesion of seborrhoeic dermatitis and psoriasis.J. Invest. Dermatol. 46:109.
10. Brody I. 1984. Dermal and epidermal involvement in the evolution of acute eruptive guttate psoriasis vulgaris. J. Invest. Dermatol. 82:465.
11. Schubert C., and E. Christophers. 1985. Mast cells and macrophages in early relapsing psoriasis. Arch. Dermatol. Res. 277:352.
12. Parent D., B.A. Bernard, C. Desbas, M. Heenen, and M.Y. Darmon. 1990. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology.J. Invest. Dermatol. 95:333.
13. Malhotra R., K.S. Stenn, L.A. Fernandez, and I.M. Braverman. 1989. The angiogenic properties of normal and psoriatic skin associate with the epidermis—not the dermis. Lah Invest. 61:162.
14. Dvorak H.F., N.S. Orenstein, A.C. Carvalho, W.H. Churchill, A.M. Dvorak, S.J. Galli, J. Feder, A.M. Bitzer, J. Ryp-sysc, and P. Giovinco. 1979. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122:166.
15. Senger D.R., S.J. Galli, A.M. Dvorak, C.A. Peruzzi, V.S. Harvey, and H.F. Dvorak. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Wash. DC). 219:983.
16. Senger D.R., L. Van De Water, L. Brown, J. Nagy, K.-T. Yeo, T.-K. Yeo, B. Berse, R. Jackman, A. Dvorak, and H.F. Dvorak. 1993. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303.
17. Berkman, R.A., M.J. Merrill, W.C. Reinhold, W.T. Monacci, A. Saxena, W.C. Clark, J.T. Robertson, I.U. Ali, and E.H. Oldfield. 1993. Expression of the vascular permeability factor/ vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91:153.
18. Brown L.F., K.-T. Yeo, B. Berse, T.-K. Yeo, D.R. Senger, H.F. Dvorak, and L. Van De Water. 1992. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176:1375.
19. Plate H., G. Breier, H.A. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (Lond.). 359:845.
20. Brown L.F., B. Berse, R.W. Jackman, K. Tognazzi, E J. Man-seau, D.R. Senger, and H.F. Dvorak. 1993. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53:4727.
21. Brown L.F., B. Berse, R.W. Jackman, K. Tognazzi, E.J. Man-seau, H.F. Dvorak, and D.R. Senger. 1993. Vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143:1255.
22. Senger D.R., C.A. Perruzzi, J. Feder, and H.F. Dvorak. 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:5629.
23. Keck P.J., S.D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, D.T. Connolly. 1989. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Wash. DC). 246:1309.
24. Leung D.W., G. Cachianes, W.-J. Kuang, D.V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Wash. DC). 246:1309.
25. Connolly D.T., D.M. Heuvelman, R. Nelson, J.V. Olander, B.L. Eppley, J.J. Delfino, N.R. Siegel, R.M. Leimgruber, and J. Feder. 1989. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1470.
26. Ferrara N., and W.J. Henzel. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:851.
27. Gospodarowicz D., J.A. Abraham, and J. Schilling. 1989. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl. Acad. Science USA. 86:7311.
28. Gottlieb A.B., C.K. Chang, D.N. Posnett, B. Fanelli, and J.P. Tam. 1988. Detection of transforming growth factor x in normal, malignant, and hyperproliferative human keratinocytes. J. Exp. Med. 167:670.
29. Elder J.T., G.T. Fisher, P.B. Lindquist, G.L. Bennett, M.R. Pittelkow, R.J. Coffey, L. Ellingsworth, R. Derynck, and J.J. Voorhees. 1989. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (Wish. DC). 243:811.
30. Berse B., L.F. Brown, L. Van De Water, H.F. Dvorak, and D.R. Senger. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell. 3:211.
31. Dvorak H.F., T.M. Sioussat, L.F. Brown, B. Berse, J.A. Nagy, A. Sotrel, E.J. Manseau, L. Van de Water, and D.R. Senger. 1991. Distribution of vascular permeability factor (vascular en-dothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174:1275.
32. Sioussat T.M., H.F. Dvorak, T.A. Brock, and D.R. Senger. 1993. Inhibition of vascular permeability factor (vascular endothelial growth factor) with anti-peptide antibodies. Arch. Biochem. Biophys. 301:15.
33. Detmar M., and C.E. Orfanos. 1990. Tumor necrosis factoralpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human ker-atinocytes in vitro. Arch. Dermatol. Res. 282:238.
34. Detmar M., S. Tenorio, U. Hettmannsperger, Zb. Ruszczak, and C.E. Orfanos. 1992. Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J. Invest. Dermatol 98:147.
35. Claffey K.P., W.O. Wilkinson, and B.M. Spiegelman. 1992. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J. Biol. Chem. 267:16137.
36. Masiakowski R, R. Breathnach, J. Bloch, J. Gannon, A. Krust, and P. Chambon. 1982. Cloning of cDNA sequences of hormone-regulated genes from the MCF-γ human breast cancer cell line. Nucleic Acids Res. 10:7895.
37. Yeo K.-T, H.H. Wang, J.A. Nagy, T.M. Sioussat, S.R. Leed-better, A.J. Hoogewerf, Y. Zhou, E.M. Masse, D.R. Senger, and H.F. Dvorak. 1993. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory infusions. Cancer Res. 53:2912.
38. Detmar M., A. Mayer-da-Silva, R. Stadler, and C.E. Orfanos. 1989. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J. Invest. Dermatol. 93:70.
39. Schreiber A., M.E. Winkler, and R. Derynck. 1986. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science (Wash. DC). 232:1250.
40. Derynck R., D.V. Goeddel, A. Ullrich, J.U. Gutterman, R.D. Williams, T.S. Bringman, and W.H. Berger. 1987. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 47:707.
41. Massagué J. 1983. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptor in human placenta membranes and A 431 cells .J. Biol. Chem. 258:13614.
42. Marquardt H., M.W. Hunkapiller, L.E. Hood, and J. Todaro. 1984. Rat transforming growth factor type I: structure and relation to epidermal growth factor. Science (Wish. DC). 223: 1079.
43. 125I-epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. Dermatol. 86:260.
44. Schmid P., D. Cox, G.K. McMaster, and P. Itin. 1993. In situ hybridization analysis of cytokine, proto-oncogene and tumour suppressor gene expression in psoriasis. Arch. Dermatol. Res. 285:334.
45. Ansel J.C., J.P. Tiesman, J.E. Olerud, J.G. Krueger, J.F. Krane, D.C. Tara, G.D. Shipley, D. Gilbertson, M.L. Usui, and C.E. Hart. 1993. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J. Clin. Invest. 92:671.
46. Krane J.F., D.P. Murphy, A.B. Gottlieb, D.M. Carter, C.E. Hart, and J.G. Krueger. 1991. Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J. Invest. Dermatol. 96:983.